GOG-0286B: A RANDOMIZED PHASE II/III STUDY OF PACLITAXEL/ CARBOPLATIN/METFORMIN (NSC#91485) VERSUS PACLITAXEL/ CARBOPLATIN/PLACEBO AS INITIAL THERAPY FOR MEASURABLE STAGE III OR IVA, STAGE IVB, OR RECURRENT ENDOMETRIAL CANCER
Sponsor: GOG
Protocol number: GOG-0286B
Projected enrollment dates: January 2015 to January 2017
Official study title: GOG-0286B: A RANDOMIZED PHASE II/III STUDY OF PACLITAXEL/ CARBOPLATIN/METFORMIN (NSC#91485) VERSUS PACLITAXEL/ CARBOPLATIN/PLACEBO AS INITIAL THERAPY FOR MEASURABLE STAGE III OR IVA, STAGE IVB, OR RECURRENT ENDOMETRIAL CANCER
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02065687